Anti-metastatic effect of curcumin analog pentagamaboronon-0-fructose (PGB-0-F) against 4T1 breast cancer cells by Ertanto, Yogi et al.
Indonesian Journal of Biotechnology
VOLUME 23(2), 2018, 109-113 | RESEARCHARTICLE
Anti-metastatic effect of curcumin analog
pentagamaboronon-0-fructose (PGB-0-F) against 4T1 breast cancer cells
Yogi Ertanto1,2, Rohmad Yudi Utomo3, Riris Istighfari Jenie3,4, Ratna Asmah Susidarti3,4, and EdyMeiyanto3,4,∗
1Biotechnology Program, Graduate School of Universitas GadjahMada, Jalan Teknika Utara, Sleman, Yogyakarta 55281, Indonesia
2ArmyMedical Center, JalanMayjen Soetoyo, Cililitan, Jakarta 13640, Indonesia
3Cancer Chemoprevention Research Center, Faculty of Pharmacy, Universitas GadjahMada, Jalan Sekip Utara, Yogyakarta 55281,
Indonesia
4Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Universitas GadjahMada, Jalan Sekip Utara, Yogyakarta 55281, Indonesia
∗Corresponding author: meiyan_e@ugm.ac.id
SUBMITTED 22 Jun 2018 REVISED 29Nov 2018 ACCEPTED 22Dec 2018
ABSTRACT Development of a chemotherapeutic agent and boron carrying pharmaceutical based on triple-negative breast
cancer is important due to itsmetastatic progression. Metastases are oftenmore dangerous than the primary tumor and they
are responsible for 90% of all cancer deaths. The purpose of this study was to explore the anti-metastatic activities of the
PGB-0 complex with fructose (PGB-0-F) against 4T1 breast cancer cells. A scratch wound healing assay was carried out to
determine the migration inhibition ability of PGB-0-F, while MMP-9 expression was analysed using gelatin zymography. The
testing of anti-migration activity showed that PGB-0-F inhibited in 4T1 cells, whereas the gelatin zymography assay revealed
a suppression ofMMP-9 expression. PGB-0-F inhibited closure on 4T1metastatic breast cancer cells line comparedwith the
control. PGB-0-F decreased theMMP-9 expression level comparedwith the control. Based on these results, PGB-0-F has the
potential to be developed as a chemotherapeutic agent, and especially as an anti-metastatic agent.
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1. Introduction
Curcumin has shown anti-tumorigenic activity and tu-
mor growth inhibition by increasing ROS levels over the
threshold through inhibition of ROS metabolic enzymes.
Curcumin has potential in controlling tumor growth by
regulating ROS levels in tumor cells (Larasati et al. 2018).
However due to its instability, there are several curcumin
analogues was developed by modifying the methylene
structure with cyclopentanoe such as PGV-0 and PGV-
1. PGV-0 and PGV-1 showed higher anti-cancer activity
compared with curcumin by modulating cell cycle, induc-
ing apoptotic, and inhibiting HER2 and NF-kB activation
on MCF-7 and MCF-7/DOX (Da’i et al. 2017; Meiyanto
et al. 2014). In addition, K-PGV-0, a soluble form of PGV-
0 also performed anti-migratory effect on highly metasta-
sis breast cancer (Putri et al. 2016). Dibenzilidine boronic
acid cyclopentanone (DBBAC) or pentagamaboronon-0
(PGB-0) is a novel boron containing-curcumin analog
which is designed and synthesized by Cancer Chemopre-
vention Research Center, Universitas Gadjah Mada based
on the benzylidine cyclopentanone structure (Utomo et al.
2017). This compound has been explored for the an-
ticancer activity and boron carrying pharmaceutical for
BNCT (Boron Neuton Capture Therapy). PGB-0 pos-
sessed cytotoxic effect on MCF-7/HER2 cells through de-
creasing HER2 expression (Utomo et al. 2017). On the
other hand, PGB-0 also performed anti-migratory effect
against 4T1 breast cancer cells by modulating cell cycle,
inducing apoptosis, inhibiting migration, and decreasing
MMP-9 expression (soon will be publised). However,
common curcumin analogues as well as PGB-0 showed
poor solubility in water. Therefore several efforts are
needed in order to increase the solubility of PGB-0.
One possible strategy to improve the solubility of
PGB-0 is through a preparation of a saccharide complex
formula. Recent studies have reported a method of solubi-
lizing p-BPA (p-boronophenylalanine), the second gener-
ation of boron compounds at a neutral pH using fructose,
to yield a p-BPA-fructose complex. This p-BPA-fructose
complex performed better solubility in water compare to
free p-BPA (Yoshino et al. 1989). Based on the applica-
tion of BPA complexation with fructose, CCRC Faculty
of Pharmacy Universitas Gadjah Mada synthesized PGB-
0-F (Figure 1) by complexing PGB-0 with fructose to im-
prove solubility of PGB-0. However, there has been no
information related to the activity of PGB-0-F on metasta-
sis of breast cancer cells, especially when the type of can-
cer is triple-negative breast cancer. In this study we inves-
tigated the anti-metastatic activities of PGB-0-F against
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FIGURE 1 Chemical structure of curcumin analogue compound,
BCP: (a) PGB-0 (Utomo et al. 2017); (b) PGB-0-F.
highly metastatic breast cancer cells, 4T1. The study was
conducted by observing cell migration by scratch wound
healing assay and protein activity of MMP-9 by gelatin
zymograph. The result of this study will be used for fur-
ther experiment in order to develop novel anti-metastasis
agents from PGB-0-Fructose complex.
2. Materials andmethods
2.1. Chemicals
PGB-0-F was synthetized by Cancer Chemoprevention
Research Center, Faculty of Pharmacy, Universitas Gad-
jah Mada. Doxorubicin was purchased from Sigma.
2.2. Cell Culture
Breast cancer cell line culture type 4T1 was obtained
from Prof. Masashi Kawaichi, M.D., Ph.D (Nara Insti-
tute of Science and Technology, NAIST, Japan). The cells
were maintained in Dulbecco’s Modified Eagles Medium
(DMEM) high glucose (Sigma) with 10% FBS (Sigma),
HEPES, sodium bicarbonate, 1000 U/mL of Penicilin-
1000 U/ml of Streptomycin and 0.5 µg/mL Fungizone
(Gibco).
2.3. Scratch wound healing assay
The 4T1 breast cancer cells were seeded with 7.5x104
cells/well density in well-plate and incubated for 24 h at
37°C until reaching confluence of 80%. Medium was re-
moved and cultured cell was washed with 100 µL PBS
(Sigma). Then, cells were added with medium contain-
ing 0.5% FBS for starvation and being incubated for 22 h.
Each well was scratched in the bottom center of the well
within cell layer by using yellow tip and treated with Dox-
orubicin 10 nM as positive control, PGB-0-F, and com-
bination of both compounds. The culture then incubated
for 48 h at 37°C. The cell migration were documented in
0, 18, 24 and 42 h under inverted microscope (Olympus)
and captured by digital camera (Samsung).
2.4. Gelatin-zymographmethods
Gelatin zymography was performed to quantify the matrix
metalloproteinase-9 (MMP-9) activity. Briefly, 4T1 cells
were culture in 6-well plates (2 x 105 cells/well) followed
by treatment with Doxorubicin 10 nM, 0, 4.25, 8.5, and
17 µM of PGB-0-F, or combination of them in starvation
medium for 24 h. After treatment, the supernatant (condi-
tioned medium) for each sample was collected and then
separated by 8% SDS-PAGE supplemented with 0.1%
gelatin. Next, the gel was incubated in 2% of Triton-X 100
(Merck, New Jersey, USA) in water for 30 min at room
temperature and the gel was then removed from solution.
Furthermore incubation buffer, consist of 40mMTris-HCl
pH 8,10 mM CaCl2, 0.02% NaN3, was added to gel and
incubated again at 37°C for 18–20 h. Then, the gel was
stained using Coomassie Brilliant Blue R-250 solution and
de-stained until clear bands with blue backgroundwere ob-
served. Those bandswere documented and analyzed using
ImageJ 1.51j8 Java 1.8.0_112 software.
3. Results
3.1. Anti-migratory effect of PGB-0-F on 4T1 cells
The purpose of this study is to develop PGB-0-F as
novel anti-metastasis agents. First, cells migration need
to be observed as the initial steps of cells metastasis.
Dox at low concentration (10 nM) was used as known
chemotherapy that induced migration (Bandyopadhyay
et al. 2010). Scratch wound healing assay was conducted
to observe cells migration after various concentration un-
der IC50value, 1/8, ¼, and ½ of IC50 (Figure 3b). After 42
h observation, Dox increased the % closure up to 100%
indicating the migratory effect. On the other hand, sin-
gle treatment of PGB-0-F showed similar profile with un-
treated cells. Interestingly, combination of Dox with all
concentration of PGB-0-F decreased % closure up to 52–
73%. Hence, treatment of PGB-0-F can decrease migra-
tion induction by Dox. The result needs to be confirmed
with the expression of certain protein played role on cells
migration or invasion.
3.2. Effect of PGB-0-F onMMP-9 expression
Cancer cells migration and invasion was tightly regulated
by certain proteins especially Matrix Metalloproteinase 9
(MMP-9). Role ofMMP-9 on cellsmigration and invasion
was to degrade extracellular matrix (ECM) around cancer
cells (Reunanen and Kähäri 2013). To observe possible ef-
fect of PGB-0-F on decreasing expression ofMMP-9, gela-
tine zymmograph was performed on 4T1 cells. Low con-
centration of Dox (10 nM) increased MMP-9 expression
which confirmed the migratory effect on scratch wound
healing assay. In contrast, both single treatment of PGB-
0-F and its combination with Dox did not affect MMP-9
expression. Hence, anti-migratory effect of PGB-0-F on
Dox induction possibly through other proteins.
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FIGURE 2 Effect of PGB-0-F on 4T1 Cells Migration. 4T1 cells (7.5
× 104 cells/well) were treated with PGB-0-F in the concentration
as indicated in the figure, then subjected for scratchwound healing
assay. (a) Themorphologyof the cells after scratchand treatedwith
PGB-0-F. Observations were made after 18, 24 and 42 h of treat-
ment under an invertedmicroscopewithmagnification of 100x. (b)
Thepercentageof4T1cells closureafter treatment. Theareaof the
scratchwas analyzedusing ImageJ then%closurewas calculated in
accordance with the procedures of the analysis (p<0.05).
4. Discussion
Inhibition of tumor cell migration is crucial in the thera-
peutic and inhibition of cancer spread, especially in metas-
tasis. Thus, it is necessary to develop anti-metastatic agent.
Previous research showed that PGB-0 has anti-migration
effect and MMP-9 expression inhibition activity (unpub-
lished data). MMP-9 is a family member of zinc- and
calcium-dependent endopeptidases, 92 kDa protein which
has numerous cell activities, involving in various physio-
logical functions, such as cell-cell contact, tissue remodel-
ing cell migration and cellular differentiation (Vandooren
et al. 2013).
Other study using boron containing compound, phen-
ylboronic acid showed that this compound has potency
as selective inhibitor of cancer cell migration and viabil-
ity without effecting non-tumorigenic cell lines (Bradke
et al. 2008; McAuley et al. 2011). The main purpose of
this study is to explore the potential metastasis-inhibitory
of PGB-0-F on triple-negative breast cancer cells, 4T1.
In this study, 4T1 cells were used as the model of hu-
man metastatic breast cancer cells because it is highly
metastatic breast cancer cells. This cells can metastasize
to liver, lung, bone and brain, making it a good model of
human metastatic breast cancer (DuPré et al. 2007; Hepp-
ner et al. 2000).
(a)
(b)
FIGURE3Result ofMMP-9ExpressionwithPGB-0-F and combina-
tion with doxorubicin treatment (24 h): (a) band of MMP-9 Expres-
sion; (b) intensity quantification ofMMP-9 band.
Doxorubicin is usually used as first-line treatment of
several type of cancer especially triple-negative breast
cancer. Prolonged use of doxorubicin has a toxicity ef-
fect such as cardiotoxicity and hepatotoxicity (Wallace
2003). Other research showed that doxorubicin at low
dose can enhanced cancer cell migration by induced lamel-
lipodia formation (Amalina et al. 2017). Previous stud-
ies showed the inbitory activity of migration of PGB-0
(Pentagamaboronon-0-frucose) in 4T1 cells (Kusumastuti
et al., unpublished data).
Previous study showed that PGB-0-F as an anti-cancer
agent which has cytotoxic effect of 4T1 cells with IC50 val-
ues of 33 µM (Meiyanto et al., unpublished data), while
PGB-0 has IC50 value of 300 µM in 4T1 cells (Kusumas-
tuti et al., unpublished data), and 270 µM in MCF-7/Her2
cells (Utomo et al. 2017). In this present study, we also
observed the inhibition of cancer cell migration as the one
of parts of metastasis process by treatment of PGB-0-F
through scratch wound healing assay. Cell migration is
part of the metastasis process. Based on the percent graph
of 4T1 cell closure (Figure 3a) the treatment of PGB-0-F
with concentration of 4.25 and 8.5 µM have not demon-
strated any migration inhibitory activity in all time course
but enhanced migration of 4T1 cell by showing a % clo-
sure profile of the cell similar to cell control’s (untreated).
In the PGB-0-F concentration of 17 µM, 4T1 cells began
to effect inhibition of cell migration in 42nd hour, but no
significant effect in 18th and 24th hour.
The treatment of doxorubicin 10 nM showed higher
% closure than untreated cells, it means that doxorubicin
induced cell migration. Previous result that doxorubicin
induced lamelipodia formation and cell migration in 4T1
and MCF-7/Her2 cells (Amalina et al. 2017). Further-
more, combination treatment of PGB-0-F and doxorubicin
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showed inhibition of 4T1 cell migration in 42 h incuba-
tion time. At this incubation time both single PGB-0-F ½
IC50 treatment and its combination with 10 nM doxoru-
bicin showed significant differences with the difference
in percentage closing percentages with consecutive values
of 12% and 22%, respectively, compared with the con-
trol of cells without treatment. Whereas when PGB-0-F
treatment with doxorubicin 10 nM compared with a sin-
gle treatment doxorubicin 10 nM resulted in a closing per-
centage percentage of 48%. Overall, PGB-0-F treatment
in three doses, 1/8, 1/4, and 1/2 IC50.
Since in the breast cancer patients there is a signifi-
cant association between highMMP9 expression and poor
survival (Song et al. 2013), therefore the MMP-9 expres-
sion would be a potential therapeutic target to inhibit the
development of cancer metastasis. Curcumin analogue
PGB-0-F showed tendency of inhibitory effect of MMP-
9 expression in gelatin zymograph assay in 24 h treatment.
Previous study showed that PGB-0 also showed the inhi-
bition effect of MMP-9 expression (to be published else-
where). Curcumin itself showed the inhibition of MMP-
9 expression by inhibiting MAPKs phosphorylation (Cao
et al. 2014). Other research showed that simultaneous
silencing of MMP9 in breast cancer cells decreased the
wound healing, migratory, invasive and adhesive capacity
of the cells by increasing cell-cell adhesion and modulat-
ing EMT (Epithelial-to-Mesenchymal Transition) genes
(Moirangthem et al. 2016).
5. Conclusions
PGB-0-F exhibits anti-migration effect against doxoru-
bicin treatment cells. PGB-0-F also inhibits MMP-9 ex-
pression which may have the potential to inhibit tumor in-
vasion.
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